The stock of Vical Incorporated (NASDAQ:VICL) is a huge mover today! About 75,115 shares traded hands or 48.76% up from the average. Vical Incorporated (NASDAQ:VICL) has declined 38.00% since April 27, 2016 and is downtrending. It has underperformed by 43.23% the S&P500.
The move comes after 5 months negative chart setup for the $25.04M company. It was reported on Nov, 30 by Barchart.com. We have $2.24 PT which if reached, will make NASDAQ:VICL worth $1.00 million less.
Analysts await Vical Incorporated (NASDAQ:VICL) to report earnings on March, 13. They expect $-0.26 EPS, up 13.33% or $0.04 from last year’s $-0.3 per share. After $-0.24 actual EPS reported by Vical Incorporated for the previous quarter, Wall Street now forecasts 8.33% negative EPS growth.
According to Zacks Investment Research, “Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs.”
More news for Vical Incorporated (NASDAQ:VICL) were recently published by: Seekingalpha.com, which released: “What’s Up With Vical?” on January 15, 2014. Globenewswire.com‘s article titled: “Vical Announces $7.8 Million Equity Investment by Partner, AnGes MG” and published on August 01, 2016 is yet another important article.
VICL Company Profile
Vical Incorporated, incorporated on April 30, 1987, researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Firm has approximately four active, independent, or partnered development programs in the areas of infectious disease including a Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, including invasive Aspergillus, which are causes of morbidity and mortality in immunocompromised patients, including transplant recipients, and a completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant to prevent CMV infection before and during pregnancy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.